Clinical trials
Prostate Cancer (Diagnosis) clinical trials
Below are recruiting prostate cancer (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 427 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07271017RecruitingPhase 1
Robot-assisted prostate biopsy using a new ultrasound probe
This trial tests a robot-assisted method for taking prostate biopsies using a new type of ultrasound probe. It may help men with certain high-risk features get a more precise diagnosis.
Baltimore, MarylandAges 40–75 - NCT07285057RecruitingPhase 2
New PET scan for men with low-risk prostate cancer on active surveillance
This trial tests a new imaging test called rhPSMA-7.3 (18F) PET/CT to see if it can better detect prostate cancer in men who are on active surveillance because their cancer is considered low-risk or favorable intermediate-risk. You would also get an MRI and a biopsy as part of the study.
New York, New YorkAges 18 years+ - NCT07299292RecruitingPhase 2
Lower dose abiraterone without hormone shots for prostate cancer
This trial tests a lower dose of abiraterone (a pill that lowers testosterone) without the usual hormone-blocking shots for men with prostate cancer that needs hormone therapy. It is for patients at high risk or with early spread who have not had hormone therapy before.
Buenos AiresAges 18 years+ - NCT07363382RecruitingPhase 1/Phase 2
Testing GRPR PET Scan for Prostate Cancer
This study tests a new imaging method (GRPR PET) to help better see and stage prostate cancer. If you have prostate cancer, this scan may give doctors more detail about where the cancer is located.
Fuzhou, FujianAges 18–90 - NCT07363486RecruitingPhase 1/Phase 2
Study of 225Ac-LNC1011 for advanced prostate cancer
This trial tests a new radioactive drug called 225Ac-LNC1011 for men with a specific type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if it can shrink tumors or slow the disease.
Fuzhou, FujianAges 18–90 - NCT07369570Recruiting
Watching low-risk prostate lesions with repeat MRI scans
This trial uses repeated MRI scans to monitor prostate lesions that have a low chance of being aggressive cancer. It is for people who have suspicious spots but whose initial biopsies did not find high-grade cancer.
KuopioAges 40 years+ - NCT07393867RecruitingPhase 2
PSMA-guided radiation boost for prostate cancer
This trial tests a special type of radiation therapy (SBRT) that delivers a higher dose directly to the main tumor in your prostate, guided by a PSMA PET scan. It aims to improve cancer control while limiting side effects.
Boston, MassachusettsAges 18 years+ - NCT00923221Recruiting
Donate blood for people with prostate cancer
This trial collects blood samples from adults with prostate cancer. It may help researchers learn more about the disease or how treatments work, without directly testing a new drug in the eligibility you provided.
Bethesda, MarylandAges 18 years+ - NCT01492972RecruitingPhase 3
Lighter radiation, with or without hormone suppression
This Phase 3 trial tests whether giving a smaller amount of radiation (“hypo-fractionated” means fewer, larger sessions) can work as well as standard approaches for intermediate-risk prostate cancer. It also compares adding hormone therapy (“androgen suppression”) to radiation versus using radiation alone.
Scottsdale, ArizonaAges 18 years+ - NCT02594202Recruiting
Collecting prostate cancer care details and prostate tissue samples
This trial enrolls adults who are being evaluated or treated for possible or confirmed prostate cancer and allows researchers to collect prostate tissue. It may help improve understanding of prostate cancer over the course of diagnosis and standard care.
Bethesda, MarylandAges 18 years+ - NCT02705846Recruiting
Study tracks outcomes in men with inherited prostate cancer risks
This study looks at how prostate cancer diagnoses and treatments turn out over time. It compares men who carry rare inherited gene changes that raise prostate cancer risk with men who do not, to better understand which treatments and outcomes may differ.
Sutton, SurreyAges 18 years+ - NCT03354416Recruiting
Imaging study of prostate cancer risk and treatment outcomes
This study looks at how prostate cancer shows up on scans and how those imaging findings relate to treatment and outcomes. It may help doctors better predict risk and guide care, especially for people with higher risk or early or suspected prostate cancer.
Bethesda, MarylandAges 18 years+ - NCT06826924Recruiting
Fasting or ketones for prostate cancer
This trial tests whether a 7-day water-only fast or taking ketone supplements can help treat prostate cancer. You would have a biopsy before and after to see how the tumor responds.
Baltimore, MarylandAges 18 years+ - NCT07590934RecruitingPhase 1/Phase 2
Testing new cancer drugs for advanced prostate cancer
This study tests new anti-cancer drugs for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to find treatments that work when standard drugs no longer help.
Encino, CaliforniaAges 18–99 - NCT07398690Recruiting
MRI-guided approach for prostate cancer diagnosis
This trial tests if using MRI and a blood test called PHI can help decide who needs a prostate biopsy. It aims to avoid unnecessary biopsies while still catching cancer early.
SeoulAges 20 years+ - NCT07407283RecruitingPhase 1/Phase 2
Study of SHR-4394 combination therapy for prostate cancer
This trial tests a new drug called SHR-4394 combined with standard hormone therapy for men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination can help control the cancer.
Chengdu, SichuanAges 18–85 - NCT07414940RecruitingPhase 1/Phase 2
Actinium-225 PSMA for advanced prostate cancer after Lu-177
This trial tests a new targeted radiation drug called actinium-225 PSMA for men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Lu-177 PSMA (a similar targeted radiation therapy). It aims to see if this stronger radiation can help when the first type stops working.
LondonAges 18 years+ - NCT07422597Recruiting
MRI or risk calculator for suspected prostate cancer
This trial compares using an upfront MRI versus a risk calculator to decide who needs a prostate biopsy. It may help men with suspected localized prostate cancer avoid unnecessary biopsies.
LevangerAges 50–75 - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT07460843Recruiting
Comparing two types of prostate biopsy for diagnosis
This study compares two methods of taking prostate biopsy samples (TB+PB vs TB+6SB) to see which is better at diagnosing prostate cancer. It is for men who have a suspicious spot on their MRI and meet certain PSA or exam criteria.
Beijing, Beijing MunicipalityAges 18–85 - NCT07468708RecruitingEarly Phase 1
Testing a new imaging agent for prostate cancer
This trial tests a new radioactive tracer called ⁶⁸Ga-FC516 to see how well it works for imaging prostate cancer. It may help doctors find and monitor prostate cancer more accurately.
Guangzhou, GuangdongAges 18 years+ - NCT07468903Recruiting
Focal radiation for prostate cancer with HDR brachytherapy
This trial tests a targeted radiation treatment called HDR brachytherapy for prostate cancer that hasn't spread. It aims to treat only the cancer spots seen on MRI, which may reduce side effects.
Los Angeles, CaliforniaAges 40 years+ - NCT07484971Recruiting
Prostate cancer study in Algeria
This study looks at how prostate cancer is found and treated in Algeria. The goal is to learn more about the disease to improve care for future patients.
Adrar, AlgeriaAges 19 years+ - NCT07223385RecruitingPhase 2
Heart health check for prostate cancer patients on ARPI therapy
This trial is for men with advanced prostate cancer who are taking ARPI therapy. It offers a special heart health consultation to help manage the increased heart risk that can come with these powerful cancer treatments.
Los Angeles, CaliforniaAges 45 years+
Hear when a new Prostate Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (diagnosis)?
- Yes. Clin2 currently lists 427 recruiting prostate cancer (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.